In vitro and in vivo activities of phosphate derivatives of 9-(1,3-dihydroxy-2-propoxymethyl)-guanine against cytomegaloviruses.
The anti-cytomegalovirus activities of four phosphate derivatives of 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG) were evaluated against human, monkey and murine viruses. The 5'-mono-, 3'5'-bis(mono-), and 3',5'-cyclic monophosphate and 5'-homophosphonate forms of DHPG inhibited virus plaque formation at 1-15 microM. The cyclic phosphate and homophosphonate were more active than the other compounds against murine cytomegalovirus (MCMV) in vitro. In an in vivo MCMV infection model, DHPG homophosphonate and DHPG were equally effective at reducing mortality at greater than or equal to 10 mg/kg. The cyclic phosphate was active at 10-20 mg/kg but toxic at greater than or equal to 40 mg/kg. The phosphorylation of DHPG phosphate and DHPG phosphonate, as well as the inhibition of human cytomegalovirus DNA polymerase by their respective triphosphates, were also examined.
D000212:Acyclovir / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology* / Q000633:toxicity; D002460:Cell Line; D002478:Cells, Cultured; D003587:Cytomegalovirus / Q000187:drug effects*; D003586:Cytomegalovirus Infections / Q000188:drug therapy; D015774:Ganciclovir / Q000031:analogs & derivatives; D006147:Guanine / Q000031:analogs & derivatives / Q000494:pharmacology; D000882:Haplorhini; D006801:Humans; D051379:Mice; D019384:Nucleic Acid Synthesis Inhibitors; D010766:Phosphorylation
D000998:Antiviral Agents; D019384:Nucleic Acid Synthesis Inhibitors; C050216:9-(1-hydroxy-4-phosphinyl-2-butoxymethyl)guanine; D006147:Guanine; C050217:9-(1,3-dihydroxy-2-propoxymethyl)-guanine-bis(monophosphate); D015774:Ganciclovir; D000212:Acyclovir